How i treat acute graft-versus-host disease of the gastrointestinal tract and the liver

Blood

Volumn 127, Issue 12, 2016, Pages 1544-1550

  McDonald, George B ^a,b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; PREDNISONE; VANCOMYCIN; IMMUNOSUPPRESSIVE AGENT;

ABDOMINAL PAIN; ACUTE GRAFT VERSUS HOST DISEASE; ANOREXIA; ARTICLE; CLINICAL ARTICLE; DIARRHEA; ESOPHAGOGASTRODUODENOSCOPY; FEVER; GASTROINTESTINAL TRACT; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; LIVER; LOOSE FECES; NAUSEA; PRIORITY JOURNAL; PYLORUS GLAND; TACHYCARDIA; VOMITING; ACUTE DISEASE; ADVERSE EFFECTS; CASE REPORT; DRUG EFFECTS; GRAFT VS HOST DISEASE; IMMUNOLOGY; PATHOLOGY; PROCEDURES;

ACUTE DISEASE; GASTROINTESTINAL TRACT; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVER;

EID: 84962233390     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-10-612747     Document Type: Article

References (57)

1. Cutler C, Antin JH. Manifestations and treatment of acute graft-versus-host disease. In: Appelbaum FR, Forman SJ, Negrin RS, Antin JH, eds. Thomas' Hematopoietic Cell Transplantation. 5th ed. Oxford, UK: Wiley-Blackwell; 2016: 1012-1019.
2. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363(22): 2091-2101.
3. Hockenbery DM, Strasser SI, McDonald GB. Gastrointestinal and hepatic complications. In: Appelbaum FR, Forman SJ, Negrin RS, Antin JH, eds. Thomas' Hematopoietic Cell Transplantation. 5th ed. Oxford, UK: Wiley-Blackwell; 2016: 1140-1155.
4. Ponec RJ, Hackman RC, McDonald GB. Endoscopic and histologic diagnosis of intestinal graft-versus-host disease after marrow transplantation. Gastrointest Endosc. 1999;49(5): 612-621.
5. Shulman HM, Sharma P, Amos D, Fenster LF, McDonald GB. A coded histologic study of hepatic graft-versus-host disease after human bone marrow transplantation. Hepatology. 1988;8(3): 463-470.
6. Abraham J, Janin A, Gornet JM, et al. Clinical severity scores in gastrointestinal graft-versushost disease. Transplantation. 2014;97(9): 965-971.
7. Wu D, Hockenberry DM, Brentnall TA, et al. Persistent nausea and anorexia after marrow transplantation: a prospective study of 78 patients. Transplantation. 1998;66(10): 1319-1324.
8. Weisdorf SA, Salati LM, Longsdorf JA, Ramsay NK, Sharp HL. Graft-versus-host disease of the intestine: a protein losing enteropathy characterized by fecal alpha 1-antitrypsin. Gastroenterology. 1983;85(5):1076-1081.
9. Rodriguez-Otero P, Porcher R, Peffault de Latour R, et al. Fecal calprotectin and alpha-1 antitrypsin predict severity and response to corticosteroids in gastrointestinal graft-versus-host disease. Blood. 2012;119(24):5909-5917.
10. Rezvani AR, Storer BE, Storb RF, et al. Decreased serum albumin as a biomarker for severe acute graft-versus-host disease after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;17(11):1594-1601.
11. Hockenbery DM, Cruickshank S, Rodell TC, et al. A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisonesparing therapy for gastrointestinal graft-versushost disease. Blood. 2007;109(10):4557-4563.
12. MacMillan ML, Robin M, Harris AC, et al. A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. Biol Blood Marrow Transplant. 2015;21(4):761-767.
13. Holmberg L, Kikuchi K, Gooley TA, et al. Gastrointestinal graft-versus-host disease in recipients of autologous hematopoietic stem cells: incidence, risk factors, and outcome. Biol Blood Marrow Transplant. 2006;12(2):226-234.
14. Leisenring WM, Martin PJ, Petersdorf EW, et al. An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Blood. 2006;108(2):749-755.
15. Gooley TA, Rajvanshi P, Schoch HG, McDonald GB. Serum bilirubin levels and mortality after myeloablative allogeneic hematopoietic cell transplantation. Hepatology. 2005;41(2):345-352.
16. Socié G, Mary J-Y, Lemann M, et al. Prognostic value of apoptotic cells and infiltrating neutrophils in graft-versus-host disease of the gastrointestinal tract in humans: TNF and Fas expression. Blood. 2004;103(1):50-57.
17. Robin M, Porcher R, de Castro R, et al. Initial liver involvement in acute GVHD is predictive for nonrelapse mortality. Transplantation. 2009; 88(9):1131-1136.
18. Mielcarek M, Furlong T, Storer BE, et al. Effectiveness and safety of lower dose prednisone for initial treatment of acute graftversus-host disease: a randomized controlled trial. Haematologica. 2015;100(6):842-848.
19. Castilla-Llorente C, Martin PJ, McDonald GB, et al. Prognostic factors and outcomes of severe gastrointestinal GVHD after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2014;49(7):966-971.
20. Daneshpouy M, Socie G, Lemann M, Rivet J, Gluckman E, Janin A. Activated eosinophils in upper gastrointestinal tract of patients with graftversus-host disease. Blood. 2002;99(8): 3033-3040.
21. Levine JE, Huber E, Hammer ST, et al. Low Paneth cell numbers at onset of gastrointestinal graft-versus-host disease identify patients at high risk for nonrelapse mortality. Blood. 2013;122(8): 1505-1509.
22. Melson J, Jakate S, Fung H, Arai S, Keshavarzian A. Crypt loss is a marker of clinical severity of acute gastrointestinal graft-versus-host disease. Am J Hematol. 2007;82(10):881-886.
23. Ertault-Daneshpouy M, Leboeuf C, Lemann M, et al. Pericapillary hemorrhage as criterion of severe human digestive graft-versus-host disease. Blood. 2004;103(12):4681-4684.
24. Levine JE, Braun TM, Harris AC, et al; for the Blood and Marrow Transplant Clinical Trials Network. A prognostic score for acute graft-versus-host disease based on biomarkers: a multicenter study. Lancet Haematol. 2015;2(1):e21-e29.
25. Vander Lugt MT, Braun TM, Hanash S, et al. ST2 as a marker for risk of therapy-resistant graftversus-host disease and death. N Engl J Med. 2013;369(6):529-539.
26. Ponce DM, Hilden P, Mumaw C, et al. High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation. Blood. 2015;125(1): 199-205.
27. McDonald GB, Tabellini L, Storer BE, Lawler RL, Martin PJ, Hansen JA. Plasma biomarkers of acute GVHD and nonrelapse mortality: predictive value of measurements before GVHD onset and treatment. Blood. 2015;126(1):113-120.
28. Ferrara JL, Harris AC, Greenson JK, et al. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood. 2011;118(25):6702-6708.
29. Hansen JA, Hanash SM, Tabellini L, et al. A novel soluble form of Tim-3 associated with severe graft-versus-host disease. Biol Blood Marrow Transplant. 2013;19(9):1323-1330.
30. Andrulis M, Dietrich S, Longerich T, et al. Loss of endothelial thrombomodulin predicts response to steroid therapy and survival in acute intestinal graft-versus-host disease. Haematologica. 2012; 97(11):1674-1677.
31. Dietrich S, Falk CS, Benner A, et al. Endothelial vulnerability and endothelial damage are associated with risk of graft-versus-host disease and response to steroid treatment. Biol Blood Marrow Transplant. 2013;19(1):22-27.
32. Holtan SG, Verneris MR, Schultz KR, et al. Circulating angiogenic factors associated with response and survival in patients with acute graftversus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802. Biol Blood Marrow Transplant. 2015; 21(6):1029-1036.
33. Washington K, Jagasia M. Pathology of graftversus-host disease in the gastrointestinal tract. Hum Pathol. 2009;40(7):909-917.
34. Epstein RJ, McDonald GB, Sale GE, Shulman HM, Thomas ED. The diagnostic accuracy of the rectal biopsy in acute graft-versus-host disease: a prospective study of thirteen patients. Gastroenterology. 1980;78(4):764-771.
35. Kreisel W, Dahlberg M, Bertz H, et al. Endoscopic diagnosis of acute intestinal GVHD following allogeneic hematopoietic SCT: a retrospective analysis in 175 patients. Bone Marrow Transplant. 2012;47(3):430-438.
36. Cox GJ, Matsui SM, Lo RS, et al. Etiology and outcome of diarrhea after marrow transplantation: a prospective study. Gastroenterology. 1994; 107(5):1398-1407.
37. Damman CJ, McDonald GB. Gastrointestinal infections after solid organ and hematopoietic cell transplantation. In: Ljungman P, Snydman DR, Boeckh M, eds. Transplant Infections. 4th ed. Cham, Switzerland: Springer International; 2016.
38. Sebastián E, Martín J, McDonald GB, et al. Cryptosporidium parvum infection vs GVHD after hematopoietic SCT: diagnosis by PCR with resolution of symptoms. Bone Marrow Transplant. 2011;46(4):612-614.
39. Fisk JD, Shulman HM, Greening RR, McDonald GB, Sale GE, Thomas ED. Gastrointestinal radiographic features of human graft-vs.-host disease. AJR Am J Roentgenol. 1981;136(2): 329-336. doi:10.2214/ajr.136.2.329.
40. Mahgerefteh SY, Sosna J, Bogot N, Shapira MY, Pappo O, Bloom AI. Radiologic imaging and intervention for gastrointestinal and hepatic complications of hematopoietic stem cell transplantation. Radiology. 2011;258(3):660-671.
41. Benedetti E, Bruno B, McDonald GB, et al. Prospective qualitative and quantitative noninvasive evaluation of intestinal acute GVHD by contrast-enhanced ultrasound sonography. Bone Marrow Transplant. 2013;48(11):1421-1428.
42. Hackman RC, Wolford JL, Gleaves CA, et al. Recognition and rapid diagnosis of upper gastrointestinal cytomegalovirus infection in marrow transplant recipients. A comparison of seven virologic methods. Transplantation. 1994;57(2):231-237.
43. Ortega F, Sánchez-Fructuoso A, Cruzado JM, et al; MYVIDA Study Group. Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium. Transplantation. 2011; 92(4):426-432.
44. Ruutu T, Eriksson B, Remes K, et al; Nordic Bone Marrow Transplantation Group. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood. 2002; 100(6):1977-1983.
45. Le Vee M, Lecureur V, Stieger B, Fardel O. Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-alpha or interleukin-6. Drug Metab Dispos. 2009;37(3):685-693.
46. McDonald GB. Hepatobiliary complications of hematopoietic cell transplantation, 40 years on. Hepatology. 2010;51(4):1450-1460.
47. Strasser SI, Shulman HM, Flowers ME, et al. Chronic graft-versus-host disease of the liver: presentation as an acute hepatitis. Hepatology. 2000;32(6):1265-1271.
48. Akpek G, Boitnott JK, Lee LA, et al. Hepatitic variant of graft-versus-host disease after donor lymphocyte infusion. Blood. 2002;100(12): 3903-3907.
49. Baehr PH, Levine DS, Bouvier ME, et al. Oral beclomethasone dipropionate for treatment of human intestinal graft-versus-host disease. Transplantation. 1995;60(11):1231-1238.
50. Bolanõs-Meade J, Logan BR, Alousi AM, et al. Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. Blood. 2014;124(22): 3221-3227, quiz 3335.
51. Van Lint MT, Milone G, Leotta S, et al. Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day 15 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood. 2006;107(10):4177-4181.
52. Pidala J, Anasetti C. Glucocorticoid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2010;16(11):1504-1518.
53. Jamani K, Russell JA, Daly A, et al. Prognosis of grade 3-4 acute GVHD continues to be dismal. Bone Marrow Transplant. 2013;48(10): 1359-1361.
54. Xhaard A, Rocha V, Bueno B, et al. Steroidrefractory acute GVHD: lack of long-term improved survival using new generation anticytokine treatment. Biol Blood Marrow Transplant. 2012;18(3):406-413.
55. Petersdorf EW, Malkki M, O'Huigin C, et al. High HLA-DP expression and graft-versus-host disease. N Engl J Med. 2015;373(7):599-609.
56. Sakai M, McDonald GB. Gastrointestinal and hepatic manifestations of chronic graft versus host disease. In: Vogelsang GB, Pavletic SZ, eds. Chronic Graft versus Host Disease. New York: Cambridge University Press; 2009:216-228.
57. Kida A, McDonald GB. Gastrointestinal, hepatobiliary, pancreatic, and iron-related diseases in long-term survivors of allogeneic hematopoietic cell transplantation. Semin Hematol. 2012;49(1):43-58.